Biological treatment of patient with ulcerative colitis during pregnancy

Czech version

Authors: J. Koželuhová
Authors‘ workplace: I. interní klinika FN a LF Plzeň
Published in: Gastroent Hepatol 2011; 65(2): 75-77
Category: IBD: Case Report

Overview

A case report is presented, of a young woman with severe ulcerative colitis that proved steroid-refractory, successfully treated with infliximab. Once complete remission had been achieved, an unexpected ectopic pregnancy was detected. Urgent laparoscopic surgery had to be undertaken and a left sided salpingectomy performed. Long-term infliximab therapy continued after surgery and a further pregnancy followed within a few months. The course of second pregnancy is physiologically without complication. The author touches upon the benefits and potential hazards arising out of biological therapy in pregnant women.

Key words:
ulcerative colitis – pregnancy – infliximab

Sources

1. van der Woude JC, Kolacek S, Dotan I et al. European evidenced-based consensus on reproduction in inflammatory bowel disease. J Crohns Colitis 2010; 4(5): 493–510.

2. Lukáš M, Ďuricová D, Bortlík M et al. Doporučení pro podávání biologické terapie u idiopatických střevních zánětů. Čes a Slov Gastroent a Hepatol 2008; 62(5): 285–291.

3. Lichtenstein G, Cohen R, Feagan B et al. Safety of infliximab in Crohn's disease: data from the 5000- patient TREAT Registry. Gastroenterology 2004; 126(Suppl 4): A54.

4. Mahadevan U, Terdiman J, Church J et al. Infliximab levels in infants born to women with inflammatory bowel disease. Gastroenterology 2007; 132 (Suppl 2): A144.

5. Cheent K, Nolan J, Shariq S et al. Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J Crohns Colitis 2010; 4(5): 603–605.